Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Archives of Internal Medicine|August 1, 1978
Ectopic parathyroid hormone syndrome. Occurrence in a case undifferentiated lymphoma with bone marrow involvementJ W Goldman, F O Becker
Clinical EEG (Electroencephalography)|April 1, 1981
"Alpha-coma" in association with generalization paroxysmal (spike-wave) activity: a case reportJ W Goldman, A H Adams
Clinical EEG (Electroencephalography)|October 1, 1981
Adult onset absence status: a report of six casesJ W Goldman, G Glatstein, A H Adams
Neurology|April 1, 1981
Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugsS Haldeman, J W Goldman, J Hyde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Are liquid biopsies a surrogate for tissue EGFR testing?J W Goldman, Z S Noor, J Remon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 7, 2018
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCA Lisberg, A Cummings, J W Goldman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.
Pageof 2